Skip to main content

Table 2 Administered dinaciclib dose levels and DLTs

From: A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

Dose level (mg/m2) Number of subjects Subjects with DLT in cycle 1 DLT
0.33 1 0 None
0.66 1 0 None
1.32 1 0 None
1.85 4 0 None
2.59 4 0 None
3.63 8 1 Hypokalemia, hypocalcemia, hypophosphatemia
5.08 3 0 None
7.11 7 1 Deep vein thrombosis
10 3 0 None
12 11 1 Septic shock
14 5 2 Orthostatic hypotension (1), elevated uric acid (1)